All In Biotech

Drug Trial Radar · NCT06662669

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

A Randomized, Open, Parallel-controlled, Multi-center , Phase Ib/Ⅱ Clinical Trial of YL-13027 and/or HY-0102 Combined With AG(Nab-paclitaxel and Gemcitabine) Regimen Chemotherapy for Metastatic Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Oct 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Nov 30, 2024

Primary completion

Sep 30, 2027

Study completion Aug 30, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In Phase 1b study, six subjects will be enrolled in Arm A (YL-13027 + AG regimen) and Arm B (HY-0102 + AG regimen). The first 12 subjects will be evaluated for safety after one cycle. After safety assessment, subjects will start to enroll in Arm C (YL-13027 + HY-0102 + AG regimen). Each group is planned to include 12-20 subjects. According to the safety and efficacy results of 3 arms of subjects in phase Ib, 1-2 groups were selected for expansion, and a randomized controlled study will be conducted with the standard treatment AG (Arm 4)regimen chemotherapy.

Conditions

  • Metastatic Pancreatic Cancer

Interventions

  • YL-13027Drug

    YL-13027 is a small molecule inhibitor of the TGF-βRI target.

  • HY-0102Drug

    HY-0102 is a recombinant anti-NKG2A humanized monoclonal antibody.

  • GemcitabineDrug

    Gemcitabine is a pyrimidine antineoplastic chemotherapeutic agent.

  • Nab-paclitaxelDrug

    Paclitaxel for Injection (albumin bound) is a chemotherapeutic agent that acts as an antitumor agent by inhibiting tumor cell mitosis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: From the first dose to the date of disease progression or date of death from any cause, whichever comes first,up to 24months.
  2. Progression-free survivalTime frame: From the first dose to the date of disease progression or date of death from any cause, whichever comes first,up to 24months.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.